** Shares of cancer testing services company NeoGenomics NEO.O fall ~15% to $12.2 in morning trade
** NEO posts Q4 revenue of $172 million, missing analysts' estimates of $173.2 million, according to data compiled by LSEG
** Company reports adj. Q4 profit of 4 cents/shr, compared to analysts' estimates of 3 cents/shr
** Company forecasts net loss of $85 million to $76 million for 2025
** NEO also forecasts 2025 revenue in the range of $735 million to $745 million
** Stock down 3.2% over the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.